Scientific Poster Session III - Students Research-in-Progress

Students Research in Progress
  Monday, October 14, 2024
  01:00 PM–02:30 PM

Abstract

Introduction:

While recommended by the American Diabetes Association Standards of Care 2024 to help reduce chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2DM), prescribing of sodium-glucose cotransporter-2 inhibitors (SGLT2-i) is low in this population. Identifying SGLT2-i prescribing and adherence at a local federally qualified health center (FQHC) is vital to identifying opportunities to increase rates of use.

Research Question or Hypothesis:

What are the current prescribing and adherence rates of SGLT2-i in patients with T2DM and CKD at a local FQHC? What factors are associated with SGLT2-i prescribing and adherence?

Study Design:

Retrospective, cross-sectional descriptive study using electronic health records (EHR) and pharmacy dispensing data.

Methods:

Adults (=19-years-old) with T2DM, CKD per eGFR <60mL/min or urine microalbumin to creatinine ratios (UACR) >30mg/g for at least 3 months, and =1 provider visit between 01/01/2020- 12/31/2023 were included. Demographic information and clinical data collected including the most recent HbA1c, the two most recent eGFR and UACR, as well as prescription orders for renin-angiotensin-aldosterone system inhibitors (RASSi), and glucagon-like peptide 1 receptor agonist (GLP1-RA). A prescription order for an SGLT2-i during the study period was the primary outcome.

Results:

This research is in progress. Preliminary results identified 885 adults with T2DM and CKD. Of these, 52% were males, 69% Hispanic/Latino, 63% reported Spanish as their preferred language, and 42% were uninsured. Over the 3-year study period, 80% had been prescribed a RAASi, 51% a GLP1-RA and 48% a SGLT2-i.

Conclusion:

Prescribing rates of SGLT2-i in patients with T2DM and CKD treated at a FQHC was low, which warrants further investigation to identify factors associated with prescribing. Our next step is to assess SGLT2-i adherence to inform ways to improve access and use of SGLT2-i to help reduce progression of CKD in this vulnerable population.

Presenting Author

Andrea Garcia Ferre M.S., PharmD Candidate 2025
University of Nebraska Medical Center

Authors

Jessica Downes PharmD, BCACP, CDCES
University of Nebraska Medical Center College of Pharmacy

Donald Klepser PhD, MBA
University of Nebraska Medical Center

Carrie McAdam-Marx MCSI, PhD, RPh
University of Nebraska Medical Center